SWIFT RIVER SIMULATION: MARY JANE: MAJOR
DEPRESSIVE DISORDER EXAM PREP DOCUMENT |
2026/2027 EDITION | 150 VERIFIED QUESTIONS - 100
Questions with Answers
SWIFT RIVER SIMULATION: MARY JANE: MAJOR DEPRESSIVE DISORDER 2026-100 QUESTIONS AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for nursing and healthcare
students undertaking the Swift River Simulation focused on Mary Jane, a patient with major depressive
disorder. It contains 150 verified questions and expert solutions that align with the latest 2026/2027
academic standards and clinical guidelines. The content covers all critical aspects of psychiatric
nursing, from assessment and diagnosis to therapeutic interventions and patient education. Each
question is crafted to enhance critical thinking and clinical reasoning, ensuring students are thoroughly
prepared for their examinations and clinical practice.
Key Features:
Overview of Major Depressive Disorder: epidemiology, etiology, and pathophysiology
Diagnostic Criteria per DSM-5-TR and ICD-10: symptoms, specifiers, and differential diagnosis
Comprehensive Psychiatric Assessment: mental status exam, suicide risk assessment, and depression screening
tools
Pharmacological Interventions: antidepressants (SSRIs, SNRIs, TCAs, MAOIs), dosing, side effects, and
patient education
Non-Pharmacological Therapies: psychotherapy (CBT, interpersonal therapy), electroconvulsive therapy
(ECT), and transcranial magnetic stimulation (TMS)
Nursing Care Planning: nursing diagnoses, outcomes, and interventions for MDD
Therapeutic Communication and the Nurse-Patient Relationship in depression care
Crisis Intervention and Suicide Prevention: safety planning, hospitalization criteria, and emergency protocols
Patient and Family Education: medication adherence, lifestyle modifications, and relapse prevention
Legal and Ethical Issues: involuntary commitment, patient rights, and confidentiality
Interdisciplinary Collaboration and Case Management in mental health settings
Cultural and Developmental Considerations: age, gender, and cultural influences on depression
Simulation-Based Learning: applying Swift River Simulation scenarios to clinical decision-making
Evidence-Based Practice: latest research and guidelines for MDD management
Quality Improvement and Patient Safety: monitoring for adverse effects and complications
Review of Comorbidities: anxiety, substance use, and medical conditions associated with MDD
Updates for 2026:
- Updated to reflect the latest DSM-5-TR diagnostic criteria and treatment guidelines for major depressive
disorder.
- Incorporated new evidence-based practices for suicide risk assessment and management.
- Revised pharmacology sections to include newly approved antidepressants and updated safety warnings.
- Enhanced simulation scenarios to align with current Swift River Simulation objectives and clinical
competencies.
- Expanded coverage of telehealth and digital mental health interventions relevant to 2026-2027 practice.
Abstract:
Page 1
,This exam preparation document offers a rigorous and comprehensive review of major depressive disorder (MDD)
as presented in the Swift River Simulation featuring Mary Jane. It integrates theoretical knowledge with practical
clinical application, addressing the full spectrum of psychiatric nursing care. The content is structured to reinforce
mastery of diagnostic criteria, evidence-based interventions, and therapeutic communication. Special emphasis is
placed on suicide risk assessment, safety planning, and the nurse's role in interdisciplinary care. The 150 verified
questions are designed to challenge students' critical thinking and prepare them for high-stakes examinations.
Updated for the 2026/2027 academic year, this resource ensures alignment with current best practices and
simulation-based learning objectives. It serves as an indispensable tool for achieving a top grade and developing
clinical competence in mental health nursing.
Keywords:
Major Depressive Disorder, Swift River Simulation, Mary Jane, Psychiatric Nursing, DSM-5-TR, Suicide Risk
Assessment, Antidepressants, Therapeutic Communication
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining the underlying concepts.
Distractor explanations are provided to clarify why incorrect options are not appropriate, enhancing understanding
and retention.
Compliance Checklist:
Aligns with 2026/2027 academic standards and clinical guidelines
Covers all major domains of psychiatric nursing for MDD
Includes 150 verified questions with expert solutions
Reflects current evidence-based practice and simulation objectives
Suitable for exam preparation and clinical competency development
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of MDD 1-20 Epidemiology, etiology, risk factors, 13%
pathophysiology
Assessment and Diagnosis 21-40 DSM-5-TR criteria, mental status exam, 13%
depression scales, differential diagnosis
Pharmacological Interventions 41-60 Antidepressants, dosing, side effects, drug 13%
interactions, patient education
Non-Pharmacological Therapies 61-80 CBT, interpersonal therapy, ECT, TMS, 13%
lifestyle interventions
Nursing Care and 81-100 Nursing diagnoses, care planning, 13%
Communication therapeutic communication, patient
education
Crisis and Safety 101-120 Suicide risk assessment, safety planning, 13%
crisis intervention, legal/ethical issues
Special Populations and 121-135 Cultural considerations, age-specific care, 10%
Comorbidities comorbid anxiety/substance use
Simulation and Clinical 136-150 Swift River Simulation scenarios, 10%
Integration interdisciplinary collaboration,
evidence-based practice
Page 2
,Q1. In the Swift River simulation, Mary Jane's initial PHQ-9 score is 22. After 4
weeks of sertraline 50 mg daily, her score is 18. According to current evidence-based
guidelines, what is the most appropriate next step?
A. Switch to a different SSRI due to inadequate response
B. Increase sertraline dose to 100 mg daily
C. Augment with bupropion
D. Add cognitive behavioral therapy and continue current dose
Correct Answer: B. Increase sertraline dose to 100 mg daily
Rationale: A decrease of less than 50% in PHQ-9 score after 4 weeks indicates partial
response; guidelines recommend dose optimization before switching or augmenting.
Sertraline can be increased to a therapeutic dose (up to 200 mg) if tolerated. Switching or
augmenting is considered after 6-8 weeks of adequate dose.
Why Wrong:
A - Switching is premature at 4 weeks; dose optimization is the standard next step.
C - Augmentation is considered after 6-8 weeks of adequate monotherapy, not at 4
weeks.
D - Adding CBT is beneficial but does not replace the need to optimize
pharmacotherapy.
Reference: Gelenberg, A.J., et al. (2010). Practice Guideline for the Treatment of Patients
With Major Depressive Disorder, 3rd ed., APA.
Q2. Mary Jane mentions she has been taking St. John's Wort for her depressive
symptoms. She is also prescribed sertraline. What is the most critical nursing
intervention?
A. Discontinue the St. John's Wort immediately and notify the provider
B. Advise her to take the St. John's Wort at a different time of day
C. Monitor for signs of hypertensive crisis
D. Encourage continued use as it may enhance the SSRI effect
Correct Answer: A. Discontinue the St. John's Wort immediately and notify the
provider
Rationale: St. John's Wort is a potent CYP3A4 inducer and can also increase serotonin.
Combined with an SSRI, it poses a risk of serotonin syndrome. The safest action is to
discontinue the herbal supplement and inform the prescriber to adjust the treatment plan.
Why Wrong:
B - Separating times does not eliminate the pharmacokinetic and pharmacodynamic
interactions.
C - Hypertensive crisis is not the primary risk; serotonin syndrome is.
D - Combining them increases the risk of serotonin syndrome, not efficacy.
Page 3
, Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 15.
Q3. Mary Jane's treatment team is considering using the PHQ-9 to monitor her
depression. Which of the following statements best reflects the evidence-based use of
the PHQ-9 in clinical practice?
A. A PHQ-9 score of 10-14 indicates moderate depression and requires immediate
medication adjustment
B. The PHQ-9 can be used to diagnose MDD based solely on its score
C. A decrease of 5 points or more is considered a clinically significant response
D. The PHQ-9 is primarily a screening tool and not sensitive to change over time
Correct Answer: C. A decrease of 5 points or more is considered a clinically
significant response
Rationale: The PHQ-9 is a valid tool for monitoring treatment response; a 5-point
decrease is widely accepted as a clinically significant improvement. It is not a standalone
diagnostic tool and requires clinical confirmation. Scores of 10-14 indicate moderate
severity but do not automatically dictate medication changes.
Why Wrong:
A - Severity categories guide treatment, but any change must consider clinical context,
not just the number.
B - Diagnosis requires clinical interview; PHQ-9 is a screening tool.
D - The PHQ-9 is sensitive to change and used for monitoring.
Reference: Kroenke, K., et al. (2001). The PHQ-9: Validity of a brief depression severity
measure. J Gen Intern Med, 16(9):606-613.
Q4. Mary Jane's provider orders a cytochrome P450 (CYP2D6) genotype test before
prescribing a new antidepressant. Which of the following scenarios would most likely
lead to a poor metabolizer phenotype?
A. Two copies of a wild-type allele
B. Two copies of a loss-of-function allele
C. One copy of a loss-of-function allele and one copy of a wild-type allele
D. More than two copies of a functional allele
Correct Answer: B. Two copies of a loss-of-function allele
Rationale: Poor metabolizers have two nonfunctional alleles, leading to reduced enzyme
activity and higher drug concentrations, increasing toxicity risk. This is especially relevant
for drugs metabolized by CYP2D6, such as many antidepressants.
Why Wrong:
A - Wild-type alleles confer normal enzyme activity.
C - This is a heterozygous genotype, often resulting in intermediate metabolizer
status.
Page 4
DEPRESSIVE DISORDER EXAM PREP DOCUMENT |
2026/2027 EDITION | 150 VERIFIED QUESTIONS - 100
Questions with Answers
SWIFT RIVER SIMULATION: MARY JANE: MAJOR DEPRESSIVE DISORDER 2026-100 QUESTIONS AND
ANSWERS ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously designed for nursing and healthcare
students undertaking the Swift River Simulation focused on Mary Jane, a patient with major depressive
disorder. It contains 150 verified questions and expert solutions that align with the latest 2026/2027
academic standards and clinical guidelines. The content covers all critical aspects of psychiatric
nursing, from assessment and diagnosis to therapeutic interventions and patient education. Each
question is crafted to enhance critical thinking and clinical reasoning, ensuring students are thoroughly
prepared for their examinations and clinical practice.
Key Features:
Overview of Major Depressive Disorder: epidemiology, etiology, and pathophysiology
Diagnostic Criteria per DSM-5-TR and ICD-10: symptoms, specifiers, and differential diagnosis
Comprehensive Psychiatric Assessment: mental status exam, suicide risk assessment, and depression screening
tools
Pharmacological Interventions: antidepressants (SSRIs, SNRIs, TCAs, MAOIs), dosing, side effects, and
patient education
Non-Pharmacological Therapies: psychotherapy (CBT, interpersonal therapy), electroconvulsive therapy
(ECT), and transcranial magnetic stimulation (TMS)
Nursing Care Planning: nursing diagnoses, outcomes, and interventions for MDD
Therapeutic Communication and the Nurse-Patient Relationship in depression care
Crisis Intervention and Suicide Prevention: safety planning, hospitalization criteria, and emergency protocols
Patient and Family Education: medication adherence, lifestyle modifications, and relapse prevention
Legal and Ethical Issues: involuntary commitment, patient rights, and confidentiality
Interdisciplinary Collaboration and Case Management in mental health settings
Cultural and Developmental Considerations: age, gender, and cultural influences on depression
Simulation-Based Learning: applying Swift River Simulation scenarios to clinical decision-making
Evidence-Based Practice: latest research and guidelines for MDD management
Quality Improvement and Patient Safety: monitoring for adverse effects and complications
Review of Comorbidities: anxiety, substance use, and medical conditions associated with MDD
Updates for 2026:
- Updated to reflect the latest DSM-5-TR diagnostic criteria and treatment guidelines for major depressive
disorder.
- Incorporated new evidence-based practices for suicide risk assessment and management.
- Revised pharmacology sections to include newly approved antidepressants and updated safety warnings.
- Enhanced simulation scenarios to align with current Swift River Simulation objectives and clinical
competencies.
- Expanded coverage of telehealth and digital mental health interventions relevant to 2026-2027 practice.
Abstract:
Page 1
,This exam preparation document offers a rigorous and comprehensive review of major depressive disorder (MDD)
as presented in the Swift River Simulation featuring Mary Jane. It integrates theoretical knowledge with practical
clinical application, addressing the full spectrum of psychiatric nursing care. The content is structured to reinforce
mastery of diagnostic criteria, evidence-based interventions, and therapeutic communication. Special emphasis is
placed on suicide risk assessment, safety planning, and the nurse's role in interdisciplinary care. The 150 verified
questions are designed to challenge students' critical thinking and prepare them for high-stakes examinations.
Updated for the 2026/2027 academic year, this resource ensures alignment with current best practices and
simulation-based learning objectives. It serves as an indispensable tool for achieving a top grade and developing
clinical competence in mental health nursing.
Keywords:
Major Depressive Disorder, Swift River Simulation, Mary Jane, Psychiatric Nursing, DSM-5-TR, Suicide Risk
Assessment, Antidepressants, Therapeutic Communication
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining the underlying concepts.
Distractor explanations are provided to clarify why incorrect options are not appropriate, enhancing understanding
and retention.
Compliance Checklist:
Aligns with 2026/2027 academic standards and clinical guidelines
Covers all major domains of psychiatric nursing for MDD
Includes 150 verified questions with expert solutions
Reflects current evidence-based practice and simulation objectives
Suitable for exam preparation and clinical competency development
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of MDD 1-20 Epidemiology, etiology, risk factors, 13%
pathophysiology
Assessment and Diagnosis 21-40 DSM-5-TR criteria, mental status exam, 13%
depression scales, differential diagnosis
Pharmacological Interventions 41-60 Antidepressants, dosing, side effects, drug 13%
interactions, patient education
Non-Pharmacological Therapies 61-80 CBT, interpersonal therapy, ECT, TMS, 13%
lifestyle interventions
Nursing Care and 81-100 Nursing diagnoses, care planning, 13%
Communication therapeutic communication, patient
education
Crisis and Safety 101-120 Suicide risk assessment, safety planning, 13%
crisis intervention, legal/ethical issues
Special Populations and 121-135 Cultural considerations, age-specific care, 10%
Comorbidities comorbid anxiety/substance use
Simulation and Clinical 136-150 Swift River Simulation scenarios, 10%
Integration interdisciplinary collaboration,
evidence-based practice
Page 2
,Q1. In the Swift River simulation, Mary Jane's initial PHQ-9 score is 22. After 4
weeks of sertraline 50 mg daily, her score is 18. According to current evidence-based
guidelines, what is the most appropriate next step?
A. Switch to a different SSRI due to inadequate response
B. Increase sertraline dose to 100 mg daily
C. Augment with bupropion
D. Add cognitive behavioral therapy and continue current dose
Correct Answer: B. Increase sertraline dose to 100 mg daily
Rationale: A decrease of less than 50% in PHQ-9 score after 4 weeks indicates partial
response; guidelines recommend dose optimization before switching or augmenting.
Sertraline can be increased to a therapeutic dose (up to 200 mg) if tolerated. Switching or
augmenting is considered after 6-8 weeks of adequate dose.
Why Wrong:
A - Switching is premature at 4 weeks; dose optimization is the standard next step.
C - Augmentation is considered after 6-8 weeks of adequate monotherapy, not at 4
weeks.
D - Adding CBT is beneficial but does not replace the need to optimize
pharmacotherapy.
Reference: Gelenberg, A.J., et al. (2010). Practice Guideline for the Treatment of Patients
With Major Depressive Disorder, 3rd ed., APA.
Q2. Mary Jane mentions she has been taking St. John's Wort for her depressive
symptoms. She is also prescribed sertraline. What is the most critical nursing
intervention?
A. Discontinue the St. John's Wort immediately and notify the provider
B. Advise her to take the St. John's Wort at a different time of day
C. Monitor for signs of hypertensive crisis
D. Encourage continued use as it may enhance the SSRI effect
Correct Answer: A. Discontinue the St. John's Wort immediately and notify the
provider
Rationale: St. John's Wort is a potent CYP3A4 inducer and can also increase serotonin.
Combined with an SSRI, it poses a risk of serotonin syndrome. The safest action is to
discontinue the herbal supplement and inform the prescriber to adjust the treatment plan.
Why Wrong:
B - Separating times does not eliminate the pharmacokinetic and pharmacodynamic
interactions.
C - Hypertensive crisis is not the primary risk; serotonin syndrome is.
D - Combining them increases the risk of serotonin syndrome, not efficacy.
Page 3
, Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 15.
Q3. Mary Jane's treatment team is considering using the PHQ-9 to monitor her
depression. Which of the following statements best reflects the evidence-based use of
the PHQ-9 in clinical practice?
A. A PHQ-9 score of 10-14 indicates moderate depression and requires immediate
medication adjustment
B. The PHQ-9 can be used to diagnose MDD based solely on its score
C. A decrease of 5 points or more is considered a clinically significant response
D. The PHQ-9 is primarily a screening tool and not sensitive to change over time
Correct Answer: C. A decrease of 5 points or more is considered a clinically
significant response
Rationale: The PHQ-9 is a valid tool for monitoring treatment response; a 5-point
decrease is widely accepted as a clinically significant improvement. It is not a standalone
diagnostic tool and requires clinical confirmation. Scores of 10-14 indicate moderate
severity but do not automatically dictate medication changes.
Why Wrong:
A - Severity categories guide treatment, but any change must consider clinical context,
not just the number.
B - Diagnosis requires clinical interview; PHQ-9 is a screening tool.
D - The PHQ-9 is sensitive to change and used for monitoring.
Reference: Kroenke, K., et al. (2001). The PHQ-9: Validity of a brief depression severity
measure. J Gen Intern Med, 16(9):606-613.
Q4. Mary Jane's provider orders a cytochrome P450 (CYP2D6) genotype test before
prescribing a new antidepressant. Which of the following scenarios would most likely
lead to a poor metabolizer phenotype?
A. Two copies of a wild-type allele
B. Two copies of a loss-of-function allele
C. One copy of a loss-of-function allele and one copy of a wild-type allele
D. More than two copies of a functional allele
Correct Answer: B. Two copies of a loss-of-function allele
Rationale: Poor metabolizers have two nonfunctional alleles, leading to reduced enzyme
activity and higher drug concentrations, increasing toxicity risk. This is especially relevant
for drugs metabolized by CYP2D6, such as many antidepressants.
Why Wrong:
A - Wild-type alleles confer normal enzyme activity.
C - This is a heterozygous genotype, often resulting in intermediate metabolizer
status.
Page 4
